3 Women’s Health Stocks Are Soaring Following Roe v. Wade Ruling
Three days after the U.S. Supreme Court struck down Roe v. Wade in one of the most potentially impactful rulings of the last century, a handful of women's health stocks are on the move on Monday in response to the news.
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Earnings Preview: Dare Bioscience
Dare Bioscience (NASDAQ:DARE) is set to give its latest quarterly earnings report on Thursday, 2022-05-12. Here's what investors need to know before the announcement.
Analysts estimate that Dare Bioscience will report an earnings per share (EPS) of $-0.14.
Daré Bioscience Initiates Phase 1/2 Clinical Study Of DARE-HRT1
Daré Bioscience, Inc. (NASDAQ:DARE), a leader in women's health innovation, today announced the initiation of a Phase 1/2 clinical study of DARE-HRT1.
DARE-HRT1 is a novel intravaginal ring (IVR)
HC Wainwright & Co. Maintains Buy on Dare Bioscience, Raises Price Target to $6
HC Wainwright & Co. analyst Douglas Tsao maintains Dare Bioscience (NASDAQ:DARE) with a Buy and raises the price target from $5 to $6.